Artesunate

Generic Name: Artesunate

Brand Names: Artesunate Amivas

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₈O_₈

CAS Number: 88495-63-0

Unique Ingredient Identifier: 60W3249T9M

Background: Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin.

Artesunate was granted FDA approval on 26 May 2020.

Indication: Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients.

Associated Conditions: Acute Uncomplicated Plasmodium Falciparum Malaria, Malaria, Cerebral, Severe Malaria

Associated Therapies: -

Clinical Trials

Azithromycin Combination Therapy for the Treatment of Severe Malaria

Phase 2

Completed

Conditions: Falciparum Malaria

Interventions: Drug: Azithromycin + Artesunate
Drug: Artesunate

First Posted Date: 2011-06-15

Last Posted Date: 2013-08-23

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 75

Registration Number: NCT01374126

Locations: 🇧🇩
MARIB, Bandarban, Bangladesh

Have Malaria Infections in Kenya Become Less Responsive to Artemisinin Treatment?

Phase 4

Conditions: Malaria

Interventions: Drug: Artesunate

First Posted Date: 2010-08-27

Last Posted Date: 2018-02-23

Lead Sponsor: KEMRI-Wellcome Trust Collaborative Research Program

Target Recruit Count: 175

Registration Number: NCT01190371

Locations: 🇰🇪
Junju Dispensary, Kilifi, Kenya
🇰🇪
Kadzinuni Dispensary, Kadzinuni, Kilifi, Kenya
🇰🇪
Pingilikani Dispensary, Kilifi, Kenya

Study on the Treatment of Vivax Malaria

Phase 3

Completed

Conditions: Vivax Malaria

Interventions: Drug: Chloroquine/Primaquine
Drug: Artesunate
Drug: Chloroquine

First Posted Date: 2010-02-24

Last Posted Date: 2013-08-28

Lead Sponsor: University of Oxford

Target Recruit Count: 655

Registration Number: NCT01074905

Locations: 🇹🇭
Shoklo Malaria Research Unit, Mae Sot, Thailand

Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Terminated

Conditions: Plasmodium Falciparum Infection

Interventions: Drug: Ferroquine (SSR97193)
Drug: Placebo
Drug: artesunate

First Posted Date: 2009-10-02

Last Posted Date: 2011-06-28

Lead Sponsor: Sanofi

Target Recruit Count: 440

Registration Number: NCT00988507

Locations: 🇧🇯
Sanofi-Aventis Investigational Site Number 204001, Cotonou, Benin
🇧🇫
Sanofi-Aventis Investigational Site Number 854001, Ouagadougou, Burkina Faso
🇧🇫
Sanofi-Aventis Investigational Site Number 854003, Nouna, Burkina Faso

and more 7 locations

Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia

Phase 2

Withdrawn

Conditions: Uncomplicated Falciparum Malaria

Interventions: Drug: Artemisone/Mefloquine (AmiM3)
Drug: Artesunate

First Posted Date: 2009-07-10

Last Posted Date: 2018-08-31

Lead Sponsor: University of Oxford

Registration Number: NCT00936767

Locations: 🇰🇭
Pailin Hospital, Pailin, Cambodia

Study of Artesunate in Metastatic Breast Cancer

Phase 1

Completed

Conditions: Locally Advanced Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: artesunate

First Posted Date: 2008-10-01

Last Posted Date: 2017-08-01

Lead Sponsor: Heidelberg University

Target Recruit Count: 23

Registration Number: NCT00764036

Locations: 🇩🇪
Complementary and Integrative Medicine, Dep. Gyn. Endocrinology, Women's Hospital, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany

Artemisinin Resistance in Cambodia II

Not Applicable

Completed

Conditions: Falciparum Malaria

Interventions: Drug: Artesunate

First Posted Date: 2008-07-25

Last Posted Date: 2011-01-25

Lead Sponsor: Armed Forces Research Institute of Medical Sciences, Thailand

Target Recruit Count: 143

Registration Number: NCT00722150

Locations: 🇰🇭
Tasanh Health Center, Sam Lot District, Battambang, Cambodia

Artemisinin Resistance in Bangladesh

Not Applicable

Completed

Conditions: Malaria

Interventions: Drug: Artesunate
Drug: quinine-doxycycline

First Posted Date: 2008-03-20

Last Posted Date: 2013-08-23

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 126

Registration Number: NCT00639873

Locations: 🇧🇩
Bandarban Sadar Hospital, Bandarban Sadar, Bandarban, Bangladesh

Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Artesunate

First Posted Date: 2007-10-02

Last Posted Date: 2014-07-31

Lead Sponsor: NICHD Global Network for Women's and Children's Health

Target Recruit Count: 51

Registration Number: NCT00538382

Locations: 🇨🇩
Kingasani Maternity Clinic, Kinshasa, Congo, The Democratic Republic of the

Phase II Artesunate Study in Severe Malaria

Phase 2

Completed

Conditions: Malaria

Interventions: Drug: Artesunate

First Posted Date: 2007-08-29

Last Posted Date: 2011-09-16

Lead Sponsor: Medicines for Malaria Venture

Target Recruit Count: 200

Registration Number: NCT00522132

Locations: 🇲🇼
Queen Elizabeth Central Hospital, Blantyre, Malawi
🇬🇦
Albert Schweitzer Hospital, Lambaréné, Gabon
🇬🇦
Universite de Medecine et Science de la Sante, Libreville, Gabon

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy